Malorie Meyer

Sep 26, 2024 | outsourcedpharma.com | Louis Garguilo |Malorie Meyer |Wen-Rong Jiang |JOINN Biologics

Mabion Capacity Update July 2024: Fill/FinishMabion, a biologics CDMO with end-to-end services focusing on recombinant proteins development and production, showcases new depyrogenation, fill finish vial capabilities, and CMC analytical proficiencies. Nuclear magnetic resonance spectroscopy is powerful technique used to investigate the structure and dynamics of the drug substance in various drug formulations.

Aug 15, 2023 | bioprocessonline.com | Malorie Meyer

Article | August 15, 2023 By Malorie Meyer, Singota Solutions Project proposals are among the first steps in the partnership between a pharmaceutical company and a CDMO. The project proposal is critical to defining project scope and goals. Most of the information in the proposal is based on a questionnaire from the CDMO but can also be obtained from a formal Request for Proposal (RFP) generated by the prospective client.

Aug 15, 2023 | pharmaceuticalonline.com | Malorie Meyer

Article | August 15, 2023 By Malorie Meyer, Singota Solutions Project proposals are among the first steps in the partnership between a pharmaceutical company and a CDMO. The project proposal is critical to defining project scope and goals. Most of the information in the proposal is based on a questionnaire from the CDMO but can also be obtained from a formal Request for Proposal (RFP) generated by the prospective client.

Aug 15, 2023 | outsourcedpharma.com | Malorie Meyer |Louis Garguilo

Article | August 15, 2023 By Malorie Meyer, Singota Solutions Project proposals are among the first steps in the partnership between a pharmaceutical company and a CDMO. The project proposal is critical to defining project scope and goals. Most of the information in the proposal is based on a questionnaire from the CDMO but can also be obtained from a formal Request for Proposal (RFP) generated by the prospective client.